Skip to main content
SpringerLink
Log in

New Algorithms for the Staging of Kidney Cancer

  • Chapter
Kidney Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 116))

Abstract

Malignant renal tumors account for 2.5% of the total cancer incidence and 2% of the total cancer mortality in the US.’ Of them, renal cell carcinoma (RCC) is the most common. The estimated 5-year survival for patients with tumors confined to the kidney is 90–95%. Conversely, advanced RCC is associated with poor prognosis.’ Radiotherapy and chemotherapy are not effective and immunotherapy is currently the adjuvant therapy available. Since the natural history of RCC is unpredictable, it is important to define staging systems that may guide the therapeutic approach towards the disease and predict outcomes. Staging systems, at general should efficiently communicate key tumor characteristics, aid clinicians in the appropriate selection of therapeutic options for an individual patient, stratisfy patients’ risk of cancer progression or cancer death, and determine selection criteria for clinical trials. When a consensus regarding an accurate, universal staging system is possible, it allows outcome comparison between different demographic groups and therefore facilitates evaluation of treatment options and clinical research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee RT, Murray T, Bolden S et al, Cancer statistics, 2000. CA. Cancer. J. Clin. 50:7, 2000.

    CAS  Google Scholar 

  2. Elson PI Witte RS, and Trump DL, Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer. Res. 48:731 0, 1988.

    Google Scholar 

  3. Figlin RA, Renal cell carcinoma: management of advanced disease. J. Urol. 161:381, 1999.

    Article  PubMed  CAS  Google Scholar 

  4. Zisman A, Pantuck A, Dorey F et al, Improved prognostication of RCC using an Integrated Staging System (UISS). J. Clin. Oncol. 19:1649, 2001.

    PubMed  CAS  Google Scholar 

  5. Flocks R and Kadesky M, Malignant neoplasms of the kidney: analysis of 353 patients followed 5 years or more. Tr. Am. Ass. Gen. Surg., 49:105, 1958.

    Google Scholar 

  6. Robson C, Churchill B, and Anderson W, The results of radical nephrectomy for renal carcinoma. J. Urol. 101:297, 1969.

    PubMed  CAS  Google Scholar 

  7. Pantuck A, Zisman A, and Belldegrun A, RCC 2000• Changing the natural history of renal cell carcinoma. J. Urol. 166:1611, 2001.

    Article  PubMed  CAS  Google Scholar 

  8. Bassil B, Dosoretz DE, and Prout GR, Jr., Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J. Urol. 134:450, 1985.

    PubMed  CAS  Google Scholar 

  9. Hermanek P and Sobin L, eds. TNM classification of malignant tumors. 4 ed. UICC international union against cancer, UICC monograph series. Springer-Verlag: Berlin, New-York. 148, 1987.

    Google Scholar 

  10. Guinan P, Sobin L, Algaba F et al, TNM staging of rend cell carcinoma: Workgroup no.3-Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 80:992, 1997.

    Article  PubMed  CAS  Google Scholar 

  11. Guinan P, Frank W, Saffrin R et al, Staging and survival of patients with renal cell carcinoma. Semin. Surg. Oncol. 10: 1994.

    Google Scholar 

  12. Hermanek P and Schrott K, Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J. Urol. 144:238, 1990.

    PubMed  CAS  Google Scholar 

  13. Skinner D, Colvin R, Vermillion C et al, Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer. 28:1165, 1971.

    Article  PubMed  CAS  Google Scholar 

  14. Maldazys J and deKernion J, Prognostic factors in metastatic renal carcinoma. J. Urol. 136:376, 1986.

    PubMed  CAS  Google Scholar 

  15. Thrasher J and Paulson D, Prognostic factors in renal cancer. Urol. Clin. North. Am. 20:247, 1993.

    PubMed  CAS  Google Scholar 

  16. Zisman A, Pantuck A, Chao D et al, Reevaluation of the 1997 TNM classification for RCC: T1 and T2 cut-off point at 4.5 cm rather then 7 cm better correlates with clinical outcome. J. Urol. 166:54, 2001

    Article  PubMed  CAS  Google Scholar 

  17. Licht M, Novick A, and Goormastic M, Nephron sparing surgery in incidntal vs. suspected renal cell carcinoma. J. Urol. 152:39, 1994.

    PubMed  CAS  Google Scholar 

  18. Lerner S, Hawkins C, Blute M et al, Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J. Urol. 155:1868, 1996.

    Article  PubMed  CAS  Google Scholar 

  19. Hafez KS, Fergany AF, and Novick AC, Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J. Urol. 162, 1999.

    Google Scholar 

  20. Kinouchi T, Saiki S, Meguro N et al, Impact of tumor size on the clinical outcomes of patients with Robson State I renal cell carcinoma. Cancer. 85:689, 1999.

    Article  PubMed  CAS  Google Scholar 

  21. Igarashi T, Tobe T, Nakatsu HO et a, The impact of a 4cm. cutoff point for stratification of T1NOMO renal cell carcinoma after radical nephrectomy. J. Urol. 165:1103, 2001.

    Article  PubMed  CAS  Google Scholar 

  22. Srigley JR, Hutter RV, Gelb AB et al, Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 80:994, 1997.

    Article  PubMed  CAS  Google Scholar 

  23. Cox DR and Oakes D, Analysis of survival data. New York: Chapman and Hall, 1990.

    Google Scholar 

  24. Ljungberg B, Landberg G, and Alamdari FI, Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand. J. Urol. Nephrol. 34:246, 2000.

    Article  PubMed  CAS  Google Scholar 

  25. Lopez Hanninen E, Kirchner H, and Atzpodien J, Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 155:19, 1996.

    Article  PubMed  CAS  Google Scholar 

  26. Motzer R, Mazumbar M, Bacik J et al, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:2530, 1999.

    PubMed  CAS  Google Scholar 

  27. Minasian LM, Motzer RJ, Gluck L et al, Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11:1368, 1993.

    PubMed  CAS  Google Scholar 

  28. Landonio G, Baiocchi C, Cattaneo D et al, Retrospective analysis of 156 cases of metastatic renal cell carcinoma: evaluation of prognostic factors and response to different treatments. Tumori. 80:468, 1994.

    PubMed  CAS  Google Scholar 

  29. de Forges A, Rey A, Klink M et al, Prognostic factors of adult metastatic renal carcinoma-a multivariate analysis. Semin. Surg. Oncol. 4:149, 1988.

    Google Scholar 

  30. Palmer PA,Vinke J, Philip T et al, Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3:475, 1992.

    PubMed  CAS  Google Scholar 

  31. Mani S, Todd MB, Katz K et al, Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J. Urol. 154:35, 1995.

    Article  PubMed  CAS  Google Scholar 

  32. Citterio G, Bertuzzi A, Tresoldi M et al, Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur. Urol. 31:286, 1997.

    PubMed  CAS  Google Scholar 

  33. Fossa SD, Kramar A, and Droz JP, Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer. 30A:1310, 1994.

    Article  PubMed  CAS  Google Scholar 

  34. Zisman A, Pantuck A, Dorey F et al, Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 20:1368, 2002.

    Article  PubMed  Google Scholar 

  35. Neves RJ, Zincke H, and Taylor WF, Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J. Urol. 139:1173, 1988.

    PubMed  CAS  Google Scholar 

  36. Kanamaru H, Li B, Miwa Y et al, Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma. Urol. Res. 27:169, 1999.

    CAS  Google Scholar 

  37. Chao D, Zisman A, Pantuck A et al, Collecting duct cell carcinoma: Clinical study of a rare tumor. J. Urol. 167:71, 2001.

    Article  Google Scholar 

  38. Zisman A, Chao D, Pantuck A et al, Unclassified renal cell carcinoma: Clinical features and prognostic impact of a new histologic subtype. J. Urol. (In press). 2002.

    Google Scholar 

  39. Arozullah AM, Khuri SF, Henderson WG et al, Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann. Intern. Med. 135:847, 2001.

    PubMed  CAS  Google Scholar 

  40. Brooks-Brunn JA, Postoperative atelectasis and pneumonia: risk factors. Am. J. Crit. Care. 4:340, 1995.

    PubMed  CAS  Google Scholar 

  41. Zisman A, Pantuck A, Figlin R et al, Validation of the UCLA integrated Staging System (UISS) for patients with renal cell carcinoma. J. Clin. Oncol. 19:3792, 2001.

    PubMed  CAS  Google Scholar 

  42. Slaton J, Zisman A, Belldegrun A et al, Validation of UCLA Integrated Staging System (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma. In AUA Annual Meeting. 2002. Orlando, FL.

    Google Scholar 

  43. Zisman A, Pantuck A, Wieder J et al, Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. (submitted for publication). 2002.

    Google Scholar 

  44. Zisman A, Pantuck A, Chao H et al, UISS-based clinical algorithm to predict outcome of patients with localized and advanced renal cell carcinoma. In AUA Annual Meeting. 2002. Orlando FL.

    Google Scholar 

  45. Nadas A, On proportional hazard functions. Technometrics. 12:413, 1970.

    Article  Google Scholar 

  46. Lee E, Statistical methods for survival data analysis. Belmont, CA: Lifetime learning publications. 289, 1980.

    Google Scholar 

  47. Jones M, Philip T, Palmer P et al, The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer. Biother. 8:275, 1993.

    Article  CAS  Google Scholar 

  48. Kattan MW, Reuter V, Motzer RJ et al, A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166:63, 2001.

    Article  PubMed  CAS  Google Scholar 

  49. Kovacs G, Akhtar M, Beckwith BJ et al, The Heidelberg classification of renal cell tumours [editorial]. J. Pathol. 183:131, 1997.

    Article  PubMed  CAS  Google Scholar 

  50. Kattan MW, Potters L, Blasko JC et al, Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 58:393, 2001.

    Article  PubMed  CAS  Google Scholar 

  51. Kattan MW, Zelefsky MJ, Kupelian PA et al, Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 18:3352, 2000.

    PubMed  CAS  Google Scholar 

  52. Kattan MW, Wheeler TM, and Scardino PT, Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 17:1499, 1999.

    PubMed  CAS  Google Scholar 

  53. Kattan MW, Eastham JA, Stapleton AM et al, A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer. Inst. 90:766, 1998.

    Article  PubMed  CAS  Google Scholar 

  54. Kattan MW, Stapleton AM, Wheeler TM et al, Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 79:528, 1997.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assaf-Harofeh Medical Center, affiliated to Sadder Faculty of Medicine, Tel Aviv University, Zerifin, 70300, Israel

    D. Leibovici, A. Sella, I. Y. Siegel & A. Zisman

  2. From the Department of Urology and the Department of Oncology, Assaf-Harofeh Medical Center, affiliated to Sadder Faculty of Medicine, Tel Aviv University, Zerifin, 70300, Israel

    A. Sella

Authors
  1. D. Leibovici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Y. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Zisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, CA, USA

    Robert A. Figlin

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Leibovici, D., Sella, A., Siegel, I.Y., Zisman, A. (2003). New Algorithms for the Staging of Kidney Cancer. In: Figlin, R.A. (eds) Kidney Cancer. Cancer Treatment and Research, vol 116. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0451-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0451-1_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5083-5

  • Online ISBN: 978-1-4615-0451-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation